share_log

Arcutis Biotherapeutics | 10-Q/A: Quarterly report (Amendment)

Arcutis Biotherapeutics | 10-Q/A: Quarterly report (Amendment)

Arcutis Biotherapeutics | 10-Q/A:季度報表(修正版)
美股SEC公告 ·  2024/07/24 20:15

牛牛AI助理已提取核心訊息

Arcutis Biotherapeutics has filed Amendment No. 1 to its Q1 2024 Quarterly Report on Form 10-Q to include previously omitted information about a Rule 10b5-1 trading arrangement. The amendment specifically addresses the Original Filing dated May 14, 2024, focusing on revising Part II Item 5 "Other Information" section.The key addition to the filing reveals that Howard G. Welgus, M.D., a Board member, established a Rule 10b5-1 trading plan on March 5, 2024. The plan allows for the potential sale of up to 93,386 shares of common stock and the exercise and sale of up to 26,614 options between June 4, 2024, and May 30, 2025.The amendment maintains all other aspects of the Original Filing unchanged, with no modifications to financial statements or other disclosures. New certifications from the company's principal executive officer and principal financial officer have been included as required by Rule 12b-15 of the Securities Exchange Act of 1934, though certain certification paragraphs were omitted as no financial statements were included in this amendment.
Arcutis Biotherapeutics has filed Amendment No. 1 to its Q1 2024 Quarterly Report on Form 10-Q to include previously omitted information about a Rule 10b5-1 trading arrangement. The amendment specifically addresses the Original Filing dated May 14, 2024, focusing on revising Part II Item 5 "Other Information" section.The key addition to the filing reveals that Howard G. Welgus, M.D., a Board member, established a Rule 10b5-1 trading plan on March 5, 2024. The plan allows for the potential sale of up to 93,386 shares of common stock and the exercise and sale of up to 26,614 options between June 4, 2024, and May 30, 2025.The amendment maintains all other aspects of the Original Filing unchanged, with no modifications to financial statements or other disclosures. New certifications from the company's principal executive officer and principal financial officer have been included as required by Rule 12b-15 of the Securities Exchange Act of 1934, though certain certification paragraphs were omitted as no financial statements were included in this amendment.
Arcutis Biotherapeutics已提交2024年第一季度10-Q表格的第1號修正案,以包含之前遺漏的有關規則10b5-1交易安排的信息。該修正案特別針對2024年5月14日的原始提交,重點修訂第二部分第5項「其他信息」部分。文件的關鍵補充披露了董事會成員Howard G. Welgus萬.D.於2024年3月5日建立了一個規則10b5-1交易計劃。該計劃允許在2024年6月4日至2025年5月30日之間,最多出售93,386股普通股及行使和出售最多26,614個期權。修正案保持原始提交的所有其他方面不變,沒有對基本報表或其他披露進行修改。根據1934年證券交易法第120億.15條的要求,已包含來自公司首席執行官和信安金融財務長的新認證,儘管由於該修正案中未包含財務報表,某些認證段落被省略。
Arcutis Biotherapeutics已提交2024年第一季度10-Q表格的第1號修正案,以包含之前遺漏的有關規則10b5-1交易安排的信息。該修正案特別針對2024年5月14日的原始提交,重點修訂第二部分第5項「其他信息」部分。文件的關鍵補充披露了董事會成員Howard G. Welgus萬.D.於2024年3月5日建立了一個規則10b5-1交易計劃。該計劃允許在2024年6月4日至2025年5月30日之間,最多出售93,386股普通股及行使和出售最多26,614個期權。修正案保持原始提交的所有其他方面不變,沒有對基本報表或其他披露進行修改。根據1934年證券交易法第120億.15條的要求,已包含來自公司首席執行官和信安金融財務長的新認證,儘管由於該修正案中未包含財務報表,某些認證段落被省略。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 366

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。